Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.

ABSTRACT:

Background

Renal medullary carcinoma (RMC) is a highly aggressive cancer in need of new therapeutic strategies. The neddylation pathway can protect cells from DNA damage induced by the platinum-based chemotherapy used in RMC. We investigated if neddylation inhibition with pevonedistat will synergistically enhance antitumour effects of platinum-based chemotherapy in RMC.

Methods

We evaluated the IC₅₀ concentrations of the neddylation-activating enzyme inhibitor pevonedistat in vitro in RMC cell lines. Bliss synergy scores were calculated using growth inhibition assays following treatment with varying concentrations of pevonedistat and carboplatin. Protein expression was assessed by western blot and immunofluorescence assays. The efficacy of pevonedistat alone or in

SUBMITTER: Shapiro DD 

PROVIDER: S-EPMC10210052 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature